As of the end of Q1–Q3 2025, the share of domestic manufacturers in the Russian retail market for veterinary medicinal products (including the online channel) continues to increase — during the reporting period they accounted for approximately 55 percent of value sales, while their share in physical units exceeded 74 percent. According to the databases “Audit of Retail Sales of Veterinary Medicinal Products in Russia (total sell out)” of the analytical company RNC Pharma, more than 120 domestic companies were present in the retail segment over the first nine months of the current year.

This group includes companies whose product portfolios also contain pharmaceutical medicinal products for human use, as well as corporations that, while engaged in pharmaceutical manufacturing, also have a veterinary division. There are relatively few such corporations (seventeen), although some of them have a fairly broad assortment in the veterinary market, including unique product positions.

During the reporting period, the products of all companies identified by us accounted for no more than 2.2 percent of the value volume of the veterinary retail market. Year-on-year, the combined value sales of these companies increased by 6.6 percent.

The company Fox & Co. leads the ranking in terms of value sales, with a market share of 0.45 percent of all value sales in the veterinary retail market. Compared to Q1–Q3 2024, sales of the company’s assortment increased by 5 percent in value terms and by 1 percent in minimum dosage units (MDU). The company’s retail portfolio during the reporting period included two insecticidal-acaricidal veterinary products: Entomosan and Diazinon. In the pharmaceutical market, the company offers the pediculosis treatment Medifox based on permethrin.

Second place was held by Armavir Biological Factory (0.41 percent in value). The manufacturer has a substantial product portfolio both in the pharmaceutical market and in veterinary retail; the main focus of the company’s veterinary products is vaccines and sera. Third place, with a share of 0.36 percent in value, went to the manufacturer Silma, which produces the enterosorbent EnteroZoo, while in the pharmaceutical retail market the company offers a similar product for humans — Enterosgel. Both products hold leading positions in the enterosorbent group in their respective markets.

Binnopharm Group ranked fourth. It is noteworthy that although the corporation is one of the most prominent players in the pharmaceutical market, for veterinary purposes it currently manufactures only one product — the antibacterial medicinal product Vetbitsin. Despite a 34 percent decline in value sales, physical consumption of the product increased by 7 percent, and the brand retains leadership within the penicillin group.

The highest sales dynamics in the top ten relative to Q1–Q3 of last year were demonstrated by Ruzfarma, which also manufactures antibacterial products — value sales of its product Vetbenzicin in veterinary retail increased by 3.7 times. The companies with the broadest portfolios among the leaders are Moscow Endocrine Plant (six brands) and Kursk Biological Factory – Biok (seven brands); notably, both companies demonstrated comparable sales dynamics at 26 percent and 29 percent, respectively.

Another noteworthy example among companies is Petrovax Pharm, which offers for animals the immunomodulator Azoxivet based on azoximer bromide, analogous to Polyoxidonium, intended for humans. Despite the fact that Polyoxidonium is one of the leaders in its category, the company cannot yet boast significant success in the veterinary retail segment — during the reporting period Azoxivet ranked second to last among immunomodulating products for animals.

Table. Top 10 domestic pharmaceutical companies by value sales of veterinary medicinal products in the Russian retail market (including marketplaces), Q1–Q3 2025